Application of a cell-based protease assay for testing inhibitors of picornavirus 3C proteases

Antiviral Research

Volumn 103, Issue 1, 2014, Pages 17-24

  Van Der Linden, Lonneke ^a,b,j   Ulferts, Rachel ^a,c   Nabuurs, Sander B ^d   Kusov, Yuri ^e   Liu, Hong ^f   George, Shyla ^e   Lacroix, Céline ^b   Goris, Nesya ^g   Lefebvre, David ^h   Lanke, Kjerstin H W ^a   De Clercq, Kris ^h   Hilgenfeld, Rolf ^e,f,i   Neyts, Johan ^b   Van Kuppeveld, Frank J M ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c UTRECHT UNIVERSITY   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF LÜBECK   (Germany)

^f SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^g Okapi Sciences NV   (Belgium)

^h VETERINARY AND AGROCHEMICAL RESEARCH CENTRE   (Belgium)

ⁱ DESY   (Germany)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

3Cpro; Cell based assay; Inhibitor; Picornavirus; Protease

Indexed keywords

ASPARTIC PROTEINASE; ETOPOSIDE; FIREFLY LUCIFERASE; POLYPROTEIN; PROTEINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GAL4;

ANIMAL CELL; ANTIVIRAL THERAPY; ARTICLE; ASSAY; CELL STRAIN BHK; CELL STRAIN COS1; ENTEROVIRUS; FOOT AND MOUTH DISEASE VIRUS; GENETIC TRANSFECTION; IN VITRO STUDY; MOLECULAR DOCKING; NONHUMAN; PICORNAVIRUS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEASE ASSAY; PROTEIN DEGRADATION; VIRUS REPLICATION; WESTERN BLOTTING;

3C(PRO); CELL-BASED ASSAY; INHIBITOR; PICORNAVIRUS; PROTEASE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CYSTEINE ENDOPEPTIDASES; DRUG EVALUATION, PRECLINICAL; GENES, REPORTER; HUMANS; LUCIFERASES, FIREFLY; PICORNAVIRIDAE; PROTEASE INHIBITORS; VIRAL PROTEINS;

EID: 84892731581     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.12.012     Document Type: Article

References (32)

1. W.N. Chen, J.Y. Chen, B.Y. Jiao, W.S. Lin, Y.L. Wu, L.L. Liu, and X. Lin Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion J. Virol. 86 2012 13533 13541
2. A.M. De Palma, W. Heggermont, K. Lanke, B. Coutard, M. Bergmann, A.M. Monforte, B. Canard, E. De Clercq, A. Chimirri, G. Purstinger, J. Rohayem, F. van Kuppeveld, and J. Neyts The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C J. Virol. 82 2008 4720 4730
3. A.M. De Palma, G. Purstinger, E. Wimmer, A.K. Patick, K. Andries, B. Rombaut, E. De Clercq, and J. Neyts Potential use of antiviral agents in polio eradication Emerg. Infect. Dis. 14 2008 545 551
4. Y. Debing, G.G. Kaplan, J. Neyts, and D. Jochmans Rapid and convenient assays to assess potential inhibitory activity on in vitro hepatitis A replication Antiviral Res. 98 2013 325 331
5. M.A. Devaney, V.N. Vakharia, R.E. Lloyd, E. Ehrenfeld, and M.J. Grubman Leader protein of foot-and-mouth disease virus is required for cleavage of the p220 component of the cap-binding protein complex J. Virol. 62 1988 4407 4409
6. P.S. Dragovich, T.J. Prins, R. Zhou, T.O. Johnson, Y. Hua, H.T. Luu, S.K. Sakata, E.L. Brown, F.C. Maldonado, T. Tuntland, C.A. Lee, S.A. Fuhrman, L.S. Zalman, A.K. Patick, D.A. Matthews, E.Y. Wu, M. Guo, B.C. Borer, N.K. Nayyar, T. Moran, L. Chen, P.A. Rejto, P.W. Rose, M.C. Guzman, E.Z. Dovalsantos, S. Lee, K. McGee, M. Mohajeri, A. Liese, J. Tao, M.B. Kosa, B. Liu, M.R. Batugo, J.P. Gleeson, Z.P. Wu, J. Liu, J.W. Meador III, and R.A. Ferre Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics J. Med. Chem. 46 2003 4572 4585
7. P.S. Dragovich, T.J. Prins, R. Zhou, S.E. Webber, J.T. Marakovits, S.A. Fuhrman, A.K. Patick, D.A. Matthews, C.A. Lee, C.E. Ford, B.J. Burke, P.A. Rejto, T.F. Hendrickson, T. Tuntland, E.L. Brown, J.W. Meador III, R.A. Ferre, J.E. Harr, M.B. Kosa, and S.T. Worland Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as l-glutamine replacements J. Med. Chem. 42 1999 1213 1224
8. N. Goris, P.A. De, J.F. Toussaint, I. Musch, J. Neyts, and C.K. De 2′-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus Antiviral Res. 73 2007 161 168
9. N.E. Goris, P.L. Eble, M.C. de Jong, and K. De Clercq Quantification of foot-and-mouth disease virus transmission rates using published data ALTEX 26 2009 52 54
10. M.J. Grubman, M. Zellner, G. Bablanian, P.W. Mason, and M.E. Piccone Identification of the active-site residues of the 3C proteinase of foot-and-mouth disease virus Virology 213 1995 581 589
11. M. Joachims, P.C. Van Breugel, and R.E. Lloyd Cleavage of poly(A)-binding protein by enterovirus proteases concurrent with inhibition of translation in vitro J. Virol. 73 1999 718 727
12. Y. Kim, S. Lovell, K.C. Tiew, S.R. Mandadapu, K.R. Alliston, K.P. Battaile, W.C. Groutas, and K.O. Chang Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses J. Virol. 86 2012 11754 11762
13. H.G. Krausslich, M.J. Nicklin, H. Toyoda, D. Etchison, and E. Wimmer Poliovirus proteinase 2A induces cleavage of eucaryotic initiation factor 4F polypeptide p220 J. Virol. 61 1987 2711 2718
14. C.C. Lee, C.J. Kuo, T.P. Ko, M.F. Hsu, Y.C. Tsui, S.C. Chang, S. Yang, S.J. Chen, H.C. Chen, M.C. Hsu, S.R. Shih, P.H. Liang, and A.H. Wang Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds J. Biol. Chem. 284 2009 7646 7655
15. J.C. Lee, S.R. Shih, T.Y. Chang, H.Y. Tseng, Y.F. Shih, K.J. Yen, W.C. Chen, J.J. Shie, J.M. Fang, P.H. Liang, Y.S. Chao, and J.T. Hsu A mammalian cell-based reverse two-hybrid system for functional analysis of 3C viral protease of human enterovirus 71 Anal. Biochem. 375 2008 115 123
16. W. Li, N. Ross-Smith, C.G. Proud, and G.J. Belsham Cleavage of translation initiation factor 4AI (eIF4AI) but not eIF4AII by foot-and-mouth disease virus 3C protease: identification of the eIF4AI cleavage site FEBS Lett. 507 2001 1 5
17. D.Z. Lin, W.K. Qian, R. Hilgenfeld, H.L. Jiang, K.X. Chen, and H. Liu Improved synthesis of rupintrivir Sci. China-Chem. 55 2012 1101 1107
18. R.E. Lloyd, M.J. Grubman, and E. Ehrenfeld Relationship of p220 cleavage during picornavirus infection to 2A proteinase sequencing J. Virol. 62 1988 4216 4223
19. D.A. Matthews, P.S. Dragovich, S.E. Webber, S.A. Fuhrman, A.K. Patick, L.S. Zalman, T.F. Hendrickson, R.A. Love, T.J. Prins, J.T. Marakovits, R. Zhou, J. Tikhe, C.E. Ford, J.W. Meador, R.A. Ferre, E.L. Brown, S.L. Binford, M.A. Brothers, D.M. DeLisle, and S.T. Worland Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes Proc. Natl. Acad. Sci. U.S.A. 96 1999 11000 11007
20. M. Medina, E. Domingo, J.K. Brangwyn, and G.J. Belsham The two species of the foot-and-mouth disease virus leader protein, expressed individually, exhibit the same activities Virology 194 1993 355 359
21. S.B. Nabuurs, M. Wagener, and J. de Vlieg A flexible approach to induced fit docking J. Med. Chem. 50 2007 6507 6518
22. C.G. Noble, Y.L. Chen, H. Dong, F. Gu, S.P. Lim, W. Schul, Q.Y. Wang, and P.Y. Shi Strategies for development of Dengue virus inhibitors Antiviral Res. 85 2010 450 462
23. A.K. Patick, S.L. Binford, M.A. Brothers, R.L. Jackson, C.E. Ford, M.D. Diem, F. Maldonado, P.S. Dragovich, R. Zhou, T.J. Prins, S.A. Fuhrman, J.W. Meador, L.S. Zalman, D.A. Matthews, and S.T. Worland In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease Antimicrob. Agents Chemother. 43 1999 2444 2450
24. A.K. Patick, M.A. Brothers, F. Maldonado, S. Binford, O. Maldonado, S. Fuhrman, A. Petersen, G.J. Smith III, L.S. Zalman, L.A. Burns-Naas, and J.Q. Tran In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease Antimicrob. Agents Chemother. 49 2005 2267 2275
25. D.E. Schultz, M. Honda, L.E. Whetter, K.L. McKnight, and S.M. Lemon Mutations within the 5′ nontranslated RNA of cell culture-adapted hepatitis A virus which enhance cap-independent translation in cultured African green monkey kidney cells J. Virol. 70 1996 1041 1049
26. T.R. Sweeney, N. Roque-Rosell, J.R. Birtley, R.J. Leatherbarrow, and S. Curry Structural and mutagenic analysis of foot-and-mouth disease virus 3C protease reveals the role of the beta-ribbon in proteolysis J. Virol. 81 2007 115 124
27. J. Tan, S. George, Y. Kusov, M. Perbandt, S. Anemuller, J.R. Mesters, H. Norder, B. Coutard, C. Lacroix, P. Leyssen, J. Neyts, and R. Hilgenfeld 3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses J. Virol. 87 2013 4339 4351
28. L. Tong Viral proteases Chem. Rev. 102 2002 4609 4626
29. M.T. Tsai, Y.H. Cheng, Y.N. Liu, N.C. Liao, W.W. Lu, and S.H. Kung Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer Antimicrob. Agents Chemother. 53 2009 748 755
30. E. Wessels, D. Duijsings, R.A. Notebaart, W.J. Melchers, and F.J. van Kuppeveld A proline-rich region in the coxsackievirus 3A protein is required for the protein to inhibit endoplasmic reticulum-to-golgi transport J. Virol. 79 2005 5163 5173
31. J.H. Zhang, T.D. Chung, and K.R. Oldenburg A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screening 4 1999 67 73
32. P.A. Zunszain, S.R. Knox, T.R. Sweeney, J. Yang, N. Roque-Rosell, G.J. Belsham, R.J. Leatherbarrow, and S. Curry Insights into cleavage specificity from the crystal structure of foot-and-mouth disease virus 3C protease complexed with a peptide substrate J. Mol. Biol. 395 2010 375 389